FILANA THERAPEUTICS, INC.

Filana Therapeutics (FLNA) reported an officer departure in late April 2026, triggering a red-flag 8-K filing that warrants context on timing, role significance, and any related compensation or transition details. No cyber incidents were detected in the 90-day window, though absence of reported events does not eliminate underlying operational or governance risks. Our 90-day snapshot captures limited signal; the full Report extends analysis to twelve months, adds dilution risk scoring from recent equity issuances, maps the company's financing trajectory, and flags AI-detected risk signals tied to executive transitions and capital structure. The full $49 Report adds comprehensive 8-K context, dilution quantification, and forward-looking governance risk assessment.